PPMX-T002 is under clinical development by Perseus Proteomics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PPMX-T002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PPMX-T002 overview
PPMX-T002 (FF-21101) is under development for the treatment of solid tumors including pancreatic neuroendocrine tumor, ovarian cancer, liposarcoma, vaginal cancer, desmoplastic small round cell (DSRC) tumor epithelial ovarian cancer, peritoneal cancer, fallopian tube carcinoma, metastatic biliary tract cancer, triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), cholangiocarcinoma, pancreatic carcinoma and colorectal cancer. The drug is administered by injection. The drug is a radionuclide drug conjugate (RDC) which contains chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, through the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope lutetium (177Lu)/actinium (225Ac).
It was also under development for the treatment of oral cavity (mouth) cancer, papillary tumor, maxillary sinusitis, oropharyngeal cancer, hypopharyngeal cancer, non-small cell lung cancer, islet cell carcinoma and laryngeal cancer.
Perseus Proteomics overview
Perseus Proteomics (PPMX), a subsidiary of Fujifilm Holdings Corp, is a developer of antibody-based therapeutics and diagnostics, research reagents, and nuclear hormone receptor drugs. The company’s antibody products comprise nuclear receptors and epigenetics, among others. It is engaged in drug discovery, antibody research support, antibody, and reagent sales. The company’s antibodies are used for the diagnosis and treatment of diabetes, heart disease, and cancer. PPMX’s antibodies are used in life science applications including drug discovery screening, diagnostic imaging for radiation therapy, antibody-based cancer therapeutics, and detection of cancer or metabolic disease biomarkers. The company also offers transcriptome database analysis and Elisa kits. PPMX is headquartered in Tokyo, Japan.
For a complete picture of PPMX-T002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
